Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 90,326	$ 123,794
Accounts receivable, net of reserves of $3,581 in 2019 and $4,702 in 2018	269,312	248,855
Inventories	195,019	173,303
Other current assets	124,982	108,220
Total current assets	679,639	654,172
Long-Term Assets:
Property and equipment, net	533,845	437,270
Operating lease right-of-use assets (Notes 2 and 7)	80,607	0
Goodwill	239,724	214,489
Intangible assets, net	58,468	41,825
Other long-term assets	240,192	189,593
Total long-term assets	1,152,836	883,177
TOTAL ASSETS	1,832,475	1,537,349
Current Liabilities:
Accounts payable	72,172	69,534
Accrued liabilities	322,938	260,683
Line of credit	288,765	398,937
Current portion of deferred revenue	41,462	41,290
Total current liabilities	725,337	770,444
Long-Term Liabilities:
Deferred income tax liabilities	33,024	29,267
Long-term debt	698,910	601,348
Long-term deferred revenue, net of current portion	48,743	60,697
Long-term operating lease liabilities (Notes 2 and 7)	67,472	0
Other long-term liabilities	81,164	84,826
Total long-term liabilities	929,313	776,138
Total liabilities	1,654,650	1,546,582
Commitments and Contingencies (Note 15)
Stockholders’ Equity (Deficit):
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 105,711 shares in 2019 and 105,087 shares in 2018; Outstanding: 85,471 shares in 2019 and 86,100 shares in 2018	10,571	10,509
Additional paid-in capital	1,213,517	1,138,216
Deferred stock units: Outstanding: 143 units in 2019 and 162 units in 2018	4,462	4,524
Retained earnings	1,595,648	1,167,928
Accumulated other comprehensive loss	(46,182)	(41,791)
Treasury stock, at cost: 20,240 shares in 2019 and 18,988 shares in 2018	(2,600,543)	(2,288,899)
Total IDEXX Laboratories, Inc. stockholders’ equity (deficit)	177,473	(9,513)
Noncontrolling interest	352	280
Total stockholders’ equity (deficit)	177,825	(9,233)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$ 1,832,475	$ 1,537,349